StockData
Scinai Immunotherapeutics Ltd. logo

Scinai Immunotherapeutics Ltd. (SCNI) stock

SCNINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 6/30
$0.37−0.01 (-1.40%)

Close on Nov 18, 2026Market cap $1.27MP/E –Yield –

Scinai Immunotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -$7.54M. The highest annual figure on record is -$7.54M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.54M–
FY2024Dec 31, 2024-$8.64M–
FY2023Dec 31, 2023-$9.71M–
FY2022Dec 31, 2022-$11.06M–
FY2021Dec 31, 2021-$10.86M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2023Jun 30, 2023-$2.60M–
Q1 FY2023Mar 31, 2023-$3.19M–
Q2 FY2022Jun 30, 2022-$3.26M–
Q1 FY2022Mar 31, 2022-$2.62M–

More Scinai Immunotherapeutics figures

See a number that looks wrong?